Gregory Fraser
Stock Analyst at Truist Securities
(4.23)
# 139
Out of 4,479 analysts
31
Total ratings
52.63%
Success rate
17.76%
Average return
Main Sectors:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.64 | +1,157.66% | 6 | Apr 30, 2024 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $72 → $80 | $63.44 | +26.10% | 6 | Mar 1, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $7.40 | +21.62% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $6.42 | +9.03% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $32.67 | -11.23% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $17.35 | +447.55% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $11.08 | +62.45% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $9.56 | +318.41% | 2 | May 26, 2023 | |
| BHC Bausch Health Companies | Downgrades: Hold | n/a | $7.09 | - | 1 | Jul 29, 2022 |
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.64
Upside: +1,157.66%
ANI Pharmaceuticals
Mar 1, 2024
Maintains: Buy
Price Target: $72 → $80
Current: $63.44
Upside: +26.10%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $7.40
Upside: +21.62%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $6.42
Upside: +9.03%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $32.67
Upside: -11.23%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $17.35
Upside: +447.55%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $11.08
Upside: +62.45%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $9.56
Upside: +318.41%
Bausch Health Companies
Jul 29, 2022
Downgrades: Hold
Price Target: n/a
Current: $7.09
Upside: -